Radiation Oncology/Endometrium/GOG Endometrium
Jump to navigation
Jump to search
|
- GOG Website
- Wikibooks list of GOG trials
| Number | Title |
| GOG-0258 | Phase III Randomized Study of Adjuvant Chemoradiotherapy Comprising Cisplatin and Tumor Volume-Directed Radiotherapy Followed by Carboplatin and Paclitaxel Versus Carboplatin and Paclitaxel Alone in Patients With Stage III or IVA Endometrial Carcinoma |
| GOG-0249 | Phase III Randomized Study of Pelvic Radiotherapy Versus Vaginal Cuff Brachytherapy, Paclitaxel, and Carboplatin in Patients With High-Risk Stage I or II Endometrial Carcinoma |
| GOG-0247 | Study of Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Completion of Treatment in Patients With Primary or Recurrent Invasive Carcinoma of the Uterine Corpus or Uterine Cervix |
| GOG-0244 | Prospective Study of the Incidence, Risk Factors, and Impact of Lymphedema After Radical Surgery in Patients With Stage I-II Endometrial (Uterine) Cancer, Stage IA-IIA Cervical Cancer, or Stage I-IV Vulvar Cancer |
| GOG-0238 | Phase II Randomized Study of Pelvic Radiotherapy With Versus Without Cisplatin in Patients With Recurrent Endometrial Cancer |
| GOG-0233 | Phase I/II Study of the Utility of Preoperative Fludeoxyglucose F 18 Positron Emission Tomography/CT Scanning and Ferumoxtran-10 MRI Scanning Prior to Primary Chemoradiotherapy in Detecting Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix or High-Risk Endometrial Carcinoma |
| GOG-0229H | Phase II Study of MEK inhibitor AZD6244 in Patients With Recurrent or Persistent Endometrial Carcinoma |
| GOG-0210 | Study to Collect Clinical Specimens For Molecular Staging of Endometrial Carcinoma |
| GOG-0136 | Research Study of Collection of Gynecological Tumor Specimens |
| GOG-0086P | Phase II Randomized Study of Paclitaxel, Carboplatin, and Bevacizumab Versus Paclitaxel, Carboplatin, and Temsirolimus Versus Ixabepilone, Carboplatin, and Bevacizumab in Patients With Stage III-IV or Recurrent Endometrial Cancer |
| GOG-9920 | Phase I Study of Doxorubicin Hydrochloride in Combination With Intraperitoneal (IP) Paclitaxel and Intravenous or IP Cisplatin in Patients With Endometrial Cancer At High Risk for Peritoneal Failure |
| Number | Title | Publication |
| GOG-0184 | Phase III Randomized Adjuvant Study of Tumor Volume-Directed Pelvic Radiotherapy With or Without Paraaortic Radiotherapy Followed By Cisplatin and Doxorubicin With or Without Paclitaxel in Patients With Stage III Endometrial Carcinoma | PMID 19108877 |
| GOG-0156 | Phase III Randomized Study of Adjuvant Pelvic Irradiation vs DOX/CDDP for Stage IB/IC/IIA/IIB Endometrial Carcinoma | Terminated |
| GOG-9908 | Phase I Study of Doxorubicin and Cisplatin Followed By Whole Abdominal Radiotherapy in Patients With Stage III or IV Endometrial Cancer | PMID 19135232 |
| GOG-9907 | Phase I Study of Paclitaxel and Cisplatin With Radiotherapy in Patients With Stage III or IV Endometrial Cancer | PMID 18962846 |
| GOG-9905 | Phase III Randomized Study of Adjuvant Radiotherapy With or Without Cisplatin and Paclitaxel After Total Abdominal Hysterectomy and Bilateral Salpingo-oophorectomy in Patients With Stage I or II Endometrial Cancer (also RTOG 9905) | Terminated |
| GOG-9403 | Phase I Dose-Seeking Study of TAX Administered During Pelvic Irradiation for Advanced or Recurrent Cancer of the Cervix, Vagina, Endometrium, or Bladder | |
| GOG-9301 | Phase I Study of Weekly CDDP and Whole-Abdominal Radiotherapy Followed by DOX/CDDP in Patients with Stage III/IV Endometrial Carcinoma | PMID 15385116 |
| GOG-147 | Companion Protocol to Evaluate the Quality of Life in Patients with Advanced Endometrial Cancer Simultaneously Enrolled on GOG-122 | |
| GOG-122 | Phase III Randomized Trial of Whole-Abdominal Irradiation vs DOX/CDDP in Patients Who Have Undergone Maximum Debulking of Advanced Endometrial Carcinoma | PMID 16330675 |
| GOG-99 | Phase III Randomized Evaluation of Adjuvant Postoperative Pelvic Radiotherapy vs No Adjuvant Therapy for Surgical Stage I and Occult Stage II Intermediate-Risk Endometrial Carcinoma | PMID 14984936 |
| GOG-94 | Phase II Study of Whole-Abdominal Radiotherapy in Patients with Papillary Serous Carcinoma and Clear Cell Carcinoma of the Endometrium or with Maximally Debulked Advanced Endometrial Carcinoma | PMID 16213007 |
| GOG-18 | Multimodality Therapy with Surgery and Radiotherapy for Stage II Adenocarcinoma and Adeno-Acanthoma of the Endometrium | Terminated |
| GOG-17 | Radiotherapy plus Endocrine Therapy with Progestin for Stage III and Stage IV Adenocarcinoma of the Endometrium | Terminated |
| GOG-16 | Preoperative vs Postoperative Radiotherapy Adjunctive to Surgery for Stage I Adenocarcinoma of the Endometrium | Terminated |
| Number | Title | Publication |
| GOG-0248 | Phase II Randomized Study of Temsirolimus With or Without Hormonal Therapy Comprising Megestrol Acetate and Tamoxifen Citrate in Patients With Advanced, Persistent, or Recurrent Endometrial Carcinoma | |
| GOG-0229I | Phase II Study of Brivanib Alaninate in Patients With Recurrent or Persistent Endometrial Carcinoma | |
| GOG-0229G | Phase II Study of Bevacizumab and Temsirolimus in Patients With Recurrent or Persistent Endometrial Carcinoma | |
| GOG-0229F | Phase II Study of VEGF Trap in Patients With Recurrent or Persistent Endometrial Carcinoma | |
| GOG-0229E | Phase II Study of Bevacizumab in Patients With Recurrent or Persistent Endometrial Cancer | |
| GOG-0229D | Phase II Study of Lapatinib in Patients With Recurrent or Persistent Endometrial Carcinoma | |
| GOG-0229C | Phase II Study of Gefitinib in Patients With Persistent or Recurrent Endometrial Carcinoma | |
| GOG-0229B | Phase II Study of Thalidomide in Patients With Recurrent or Persistent Endometrial Cancer | PMID 17306350 |
| GOG-0224 | Phase II Randomized Study of Megestrol Acetate in Patients With Endometrial Intraepithelial Neoplasia or Atypical Endometrial Hyperplasia | |
| GOG-0211 | Phase II Pilot Study of Medroxyprogesterone in Patients With Endometrioid Adenocarcinoma of the Uterine Corpus | |
| GOG-0209 | Phase III Randomized Study of Doxorubicin, Cisplatin, Paclitaxel, and Filgrastim (G-CSF) Versus Carboplatin and Paclitaxel in Patients With Stage III or IV or Recurrent Endometrial Cancer | |
| GOG-0189 | Phase III Randomized Study of Doxorubicin, Cisplatin, Paclitaxel, and Filgrastim (G-CSF) Versus Tamoxifen and Megestrol in Patients With Stage III or IV or Recurrent Endometrial Cancer | |
| GOG-0188 | Phase II Study of Fulvestrant in Patients With Newly Recurrent, Persistent, or Metastatic Endometrial Cancer | |
| GOG-0184 | Phase III Randomized Adjuvant Study of Tumor Volume-Directed Pelvic Radiotherapy With or Without Paraaortic Radiotherapy Followed By Cisplatin and Doxorubicin With or Without Paclitaxel in Patients With Stage III Endometrial Carcinoma | |
| GOG-0181B | Phase II Study of Trastuzumab (Herceptin®) in Patients With Advanced, Recurrent, or Persistent Endometrial Adenocarcinoma | PMID 1984088 |
| GOG-0177 | Phase III Randomized Study of Doxorubicin/Cisplatin With or Without Paclitaxel and Filgrastim (G-CSF) Support in Patients with Stage III, Stage IV, or Recurrent Endometrial Cancer | |
| GOG-0163 | Phase III Randomized Study of Doxorubicin/Cisplatin vs Doxorubicin/Paclitaxel/G-CSF for Primary Stage III/IV or Recurrent Endometrial Carcinoma | |
| GOG-0156 | Phase III Randomized Study of Adjuvant Pelvic Irradiation vs DOX/CDDP for Stage IB/IC/IIA/IIB Endometrial Carcinoma | Terminated |
| GOG-0137A | Phase III Randomized Study of Estrogen Replacement Therapy Versus Placebo in Women With Stage I or II Endometrial Adenocarcinoma | |
| GOG-0129Q] | Phase II Study of Gemcitabine Hydrochloride in Patients With Recurrent or Persistent Endometrial Adenocarcinoma | |
| GOG-0129P | Phase II Study of Ixabepilone in Patients With Recurrent or Persistent Endometrial Adenocarcinoma | PMID 19451430 |
| GOG-0129O | Phase II Study of Pemetrexed Disodium in Patients With Persistent or Recurrent Endometrial Adenocarcinoma | PMID 19804902 |
| GOG-0129N | Phase II Study of Docetaxel in Patients With Recurrent or Persistent Endometrial Carcinoma | PMID 18675446 |
| GOG-0129M | Phase II Study of Flavopiridol in Patients With Recurrent or Persistent Endometrial Carcinoma | PMID 15978659 |
| GOG-0129K | Phase II Study of Oxaliplatin in Patients With Persistent or Recurrent Endometrial Carcinoma | PMID 16712905 |
| GOG-0087J | Phase II Study of Doxorubicin HCl Liposome in Patients With Recurrent or Advanced Uterine Sarcoma | PMID 15721421 |
| GOG-0086M | Phase II Study of Doxorubicin HCl Liposome in Patients With Advanced or Recurrent Endometrial Cancer | PMID 15975638 |
| GOG-0026A | Master Protocol Template for Individual Phase II Studies of New Drug Therapies in Patients With Metastatic or Recurrent Gynecologic Malignancies | |
| GOG-9908 | Phase I Study of Doxorubicin and Cisplatin Followed By Whole Abdominal Radiotherapy in Patients With Stage III or IV Endometrial Cancer | PMID 19135232 |
| GOG-9907 | Phase I Study of Paclitaxel and Cisplatin With Radiotherapy in Patients With Stage III or IV Endometrial Cancer | PMID 18962846 |
| GOG-9905 | Phase III Randomized Study of Adjuvant Radiotherapy With or Without Cisplatin and Paclitaxel After Total Abdominal Hysterectomy and Bilateral Salpingo-oophorectomy in Patients With Stage I or II Endometrial Cancer (also RTOG 9905) | Terminated |
| GOG-9902 | Quality of Life of Gynecologic Cancer Survivors | |
| GOG-9805 | Phase II Study of Amifostine for Protection Against Cisplatin and Paclitaxel Induced Neurotoxicity in Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer | PMID 14615449 |
| GOG-9405 | Phase I Study of Paclitaxel Combined with Fixed Doses of CDDP/DOX for Advanced Gynecologic Malignancies and Recurrent Bladder Cancer with or without Pelvic Irradiation | PMID 11181665 |
| GOG-9403 | Phase I Dose-Seeking Study of TAX Administered During Pelvic Irradiation for Advanced or Recurrent Cancer of the Cervix, Vagina, Endometrium, or Bladder | |
| GOG-9301 | Phase I Study of Weekly CDDP and Whole-Abdominal Radiotherapy Followed by DOX/CDDP in Patients with Stage III/IV Endometrial Carcinoma | PMID 15385116 |
| GOG-9206 | Phase II Study of Laparoscopic-Assisted Vaginal Hysterectomy/Bilateral Salpingo-Oophorectomy, Intraperitoneal Staging, and Pelvic and Aortic Lymph Node Sampling in Patients with Presumed Stage I/IIA Adenocarcinoma of the Endometrium | PMID 15086735 |
| GOG-9102 | The Effect of Alopecia on the Cancer Patient's Body Image and the Role of Audiovisual Information on Improving Body Image | |
| GOG-9101 | Phase I Study of Intraperitoneal TAX in Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma | PMID 8523061 |
| GOG-9001 | Phase I Limited-Access Study of Weekly Cisplatin and Whole-Abdominal Irradiation in Patients with Stage III/IV Endometrial Carcinoma | PMID 8946862 |
| GOG-8909 | Phase I Study of CDDP plus Cyclosporine in Patients with Refractory Gynecologic Cancer | |
| GOG-8808 | Phase I Study of Intraperitoneal Taxol in Patients with Recurrent and/or Persistent Gynecologic Carcinoma | PMID 7912515 |
| GOG-7892 | Phase II Hormone Therapy with Tamoxifen for Advanced or Recurrent Endometrial Adenocarcinoma | Terminated |
| GOG-180 | Phase II Study of Danazol in Patients with Advanced or Recurrent Endometrial Cancer | PMID 12798713 |
| GOG-168 | Phase II Study of Anastrozole (Arimidex) in Advanced, Recurrent or Persistent Endometrial Cancer | PMID 10926805 |
| GOG-167 | Prospective Study of Immediate Hysterectomy and Phase II Randomized Study of Medroxyprogesterone Acetate (Provera) Versus Medroxyprogesterone Acetate Suspension (Depo-Provera) Prior to Hysterectomy in Patients With Atypical Endometrial Hyperplasia | PMID 16400639 |
| GOG-166 | Phase II Study of High-Dose Intravenous Progesterone and Doxorubicin for Progressive Endometrial Carcinoma Resistant to Ongoing Doxorubicin Alone | |
| GOG-159 | Phase II Study of ZDX in Advanced, Recurrent, or Persistent Endometrial Cancer | |
| GOG-153 | Phase II Study of Alternating Courses of Megestrol and Tamoxifen for Recurrent or Persistent Endometrial Adenocarcinoma | PMID 14751131 |
| GOG-147 | Companion Protocol to Evaluate the Quality of Life in Patients with Advanced Endometrial Cancer Simultaneously Enrolled on GOG-122 | |
| GOG-139 | Phase III Randomized Study of DOX/CDDP Administered on Standard vs Circadian-Timed Schedules in Patients with Primary Stage III/IV/Recurrent Endometrial Carcinoma | PMID 14551299 |
| GOG-129L | Phase II Study of 6-Hydroxymethylacylfulvene (Irofulven) in Patients With Persistent or Recurrent, Refractory Endometrial Carcinoma | PMID 15122083 |
| GOG-129J | Phase II Study of Topotecan in Patients With Persistent, Recurrent, or Refractory Endometrial Carcinoma | PMID 12468321 |
| GOG-129I | Phase II Study of Pyrazoloacridine (PZA) in Patients with Recurrent or Refractory Endometrial Carcinoma | PMID 11812081 |
| GOG-129H | Phase II Study of the Effects of DOXIL in the Treatment of Recurrent or Persistent Endometrial Carcinoma | PMID 11981008 |
| GOG-129E | Phase II Study of Dactinomycin for Recurrent or Persistent Endometrial Carcinoma | PMID 10600310 |
| GOG-129C | Phase II Study of TAX for Recurrent or Persistent Endometrial Cancer | PMID 12648575 |
| GOG-129B | Phase II Study of Prolonged Oral VP-16 in Patients with Recurrent or Advanced Endometrial Cancer | |
| GOG-122 | Phase III Randomized Trial of Whole-Abdominal Irradiation vs DOX/CDDP in Patients Who Have Undergone Maximum Debulking of Advanced Endometrial Carcinoma | PMID 16330675 |
| GOG-121 | Phase II Trial of High-Dose MEG in Patients with Advanced or Recurrent Endometrial Carcinoma | |
| GOG-119 | Phase II Study of Tamoxifen plus Medroxyprogesterone for Advanced, Recurrent, or Metastatic Endometrial Carcinoma | PMID 14751130 |
| GOG-107 | Phase III Randomized Study Comparing ADR vs ADR/CACP in Patients with Recurrent Primary Stage III/IV Endometrial Carcinoma | PMID 15459211 |
| GOG-99 | Phase III Randomized Evaluation of Adjuvant Postoperative Pelvic Radiotherapy vs No Adjuvant Therapy for Surgical Stage I and Occult Stage II Intermediate-Risk Endometrial Carcinoma | PMID 14984936 |
| GOG-96 | Phase II Circadian-Timed Combination Chemotherapy with ADR/CDDP in Patients with Advanced Primary Endometrial Carcinoma | PMID 8256764 |
| GOG-94 | Phase II Study of Whole-Abdominal Radiotherapy in Patients with Papillary Serous Carcinoma and Clear Cell Carcinoma of the Endometrium or with Maximally Debulked Advanced Endometrial Carcinoma | PMID 16213007 |
| GOG-860 | Phase II Master Protocol for Chemotherapy in Patients with Advanced or Recurrent Carcinoma of the Endometrium --- TAX/G-CSF | |
| GOG-86J | Phase II Master Protocol for Treatment of Patients with Advanced or Recurrent Carcinoma of the Endometrium --- Tumor Necrosis Factor | |
| GOG-86I | Phase II Study of IFF/Mesna for Advanced or Recurrent Carcinoma of the Endometrium | |
| GOG-86E | Phase II Master Protocol for Chemotherapy in Patients with Advanced or Recurrent Carcinoma of the Endometrium --- Vincristine | PMID 8424397 |
| GOG-86D | Phase II Master Protocol for Chemotherapy in Patients with Advanced or Recurrent Carcinoma of the Endometrium --- MTX | PMID 2407104 |
| GOG-86 | Phase II Master Protocol for Advanced or Recurrent Carcinoma of the Endometrium: Phase I/II Study of Hexamethylmelamine | PMID 3141250 |
| GOG-083 | Phase II Clinico-Pathological Study of Adjuvant Chemotherapy with L-PAM in Patients with Simultaneous Endometrial and Ovarian Carcinoma | |
| GOG-81F | Master Protocol for Hormonal Treatment of Advanced or Recurrent Endometrial Carcinoma --- Phase II Tamoxifen for Disease Responsive to Progestins | PMID 11208827 |
| GOG-81 | Phase III Randomized Study of Low-Dose vs High-Dose Medroxyprogesterone Acetate (Provera) in Patients with Advanced, Persistent, or Recurrent Endometrial Carcinoma | PMID 11208827 |
| GOG-62 | Data Collection Form for Extravasation Injury with Doxorubicin | |
| GOG-48 | Phase III Provera (MPA) vs ADR vs ADR/CTX for Stage III/IV or Recurrent Endometrial Cancer | PMID 8021731 |
| GOG-28 | Phase III L-PAM/5-FU/MEG Chemotherapy vs ADR/CTX/5-FU/MEG for Primary Stage III or IV Recurrent or Residual Endometrial Cancer | PMID 6371627 |
| GOG-34 | Phase III Randomized Trial of Surgery plus Radiotherapy Followed by Chemotherapy with ADR vs Surgery plus Radiotherapy Alone in Patients with High-Risk Stage I/High-Risk Occult Stage II Endometrial Carcinoma, Including Those with Adnexal Metastases | PMID 2298404 |
| GOG-30 | Phase II Chemotherapy with Adriamycin for Endometrial Adenocarcinoma | |
| GOG-26MM | Phase II Master Protocol for Advanced, Recurrent Gynecologic Malignancies: EDAM | PMID 7900709 |
| GOG-26KK | Phase II Master Protocol for Advanced, Recurrent Endometrial Carcinoma: Merbarone | PMID 8554040 |
| GOG-26HH | Phase II Master Protocol for Advanced, Recurrent Pelvic Gynecologic Malignancies: Fluorouracil/Leucovorin | |
| GOG-26GG | Phase II Master Protocol for Advanced, Recurrent Pelvic Gynecologic Malignancies: Fazarabine | PMID 7534978 |
| GOG-26Y | Phase II Master Protocol for Advanced, Recurrent Gynecologic Malignancies: Vinblastine | PMID 2239800 |
| GOG-26W | Phase II Master Protocol for Advanced, Recurrent Gynecologic Malignancies: Echinomycin | PMID 2198794 |
| GOG-26V | Phase II Master Protocol for Advanced, Recurrent Gynecologic Malignancies: N-Methylformamide | PMID 2384305 |
| GOG-26T | Phase II Master Protocol Chemotherapy with 4'-Deoxydoxorubicin for Advanced, Recurrent Pelvic Malignancies | PMID 2557300 |
| GOG-26P | Phase II Master Protocol for Advanced, Recurrent Pelvic Malignancies: AT-125 | PMID 3700040 |
| GOG-26M | Phase II Chemotherapy with PALA for Advanced Recurrent Pelvic Malignancies | PMID 6731346 |
| GOG-26K | Phase II Chemotherapy with Chlorozotocin for Advanced, Recurrent and Metastatic Pelvic Malignancies in Progression | |
| GOG-26J | Phase II Chemotherapy with YOSHI-864 for Advanced, Recurrent Pelvic Malignancies | PMID 6288239 |
| GOG-26H | Phase II Chemotherapy with Maytansine for Advanced Recurrent Pelvic Malignancies | PMID 6869315 |
| GOG-26I | Phase II Chemotherapy with AMSA for Advanced, Recurrent Pelvic Malignancies (Cervix) | PMID 6687445 |
| GOG-26G | Phase II Master Protocol for Advanced, Recurrent Pelvic Malignancies: ICRF-159 | PMID 3953488 |
| GOG-26F | Phase II Chemotherapy with Baker's Antifol for Advanced Recurrent Pelvic Malignancies | PMID 6236163 |
| GOG-26E | Phase II Master Protocol for Advanced, Recurrent Gynecologic Malignancies: Dianhydrogalactitol | PMID 6511240 |
| GOG-26D | Phase II Master Protocol for Advanced, Recurrent Gynecologic Malignancies: VP-16 | PMID 6509456 |
| GOG-26B | Phase II Chemotherapy with Piperazinedione for Advanced Gynecologic Malignancies in Women | PMID 3754086 |
| GOG-23 | Chemotherapy with ADR/VCR/CTX for Carcinoma of the Cervix and for Adenocarcinoma of the Endometrium | |
| GOG-18 | Multimodality Therapy with Surgery and Radiotherapy for Stage II Adenocarcinoma and Adeno-Acanthoma of the Endometrium | Terminated |
| GOG-17 | Radiotherapy plus Endocrine Therapy with Progestin for Stage III and Stage IV Adenocarcinoma of the Endometrium | Terminated |
| GOG-16 | Preoperative vs Postoperative Radiotherapy Adjunctive to Surgery for Stage I Adenocarcinoma of the Endometrium | Terminated |
| GOG-15 | Modified Phase II-III Chemotherapy with CCNU or MeCCNU for Advanced Gynecologic Cancers | PMID 350400 |
| GOG-P12 | Relation of Progestin Receptor Concentration to Efficacy of Progestin Therapy for Endometrial Adenocarcinoma - Pilot Study |